Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ayala Pharmaceuticals Inc (OP: ADXS ) 0.2500 +0.0350 (+16.28%) Streaming Delayed Price Updated: 12:31 PM EDT, May 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 621 Open 0.2350 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.2150 Today's Range 0.2350 - 0.2500 52wk Range 0.1350 - 1.950 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations May 09, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome March 26, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Performance YTD -60.32% -60.32% 1 Month -53.70% -53.70% 3 Month -71.91% -71.91% 6 Month -69.51% -69.51% 1 Year -76.42% -76.42% More News Read More Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors February 20, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 From Immunome, Inc. Via Business Wire Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals February 06, 2024 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors November 06, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 October 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Closing of Merger with Biosight October 19, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 August 01, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement July 27, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors July 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting June 05, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 May 30, 2023 Via Benzinga Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 25, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update May 23, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 27, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Inc. (OTC:ADXS) Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors March 08, 2023 Via News Direct Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee March 03, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022 February 10, 2023 From Ayala Pharmaceuticals Via GlobeNewswire Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQ October 19, 2022 Via Benzinga Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement October 19, 2022 From Ayala Pharmaceuticals Via GlobeNewswire ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS March 28, 2022 From Kahn Swick & Foti, LLC Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session December 22, 2021 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session December 10, 2021 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
